STOCK TITAN

Eton Pharmaceuticals Announces Appointment of Jenn Adams to its Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary

Eton Pharmaceuticals announced the appointment of Jenn Adams to its board of directors, effective March 17, 2021. Ms. Adams brings substantial experience in the pharmaceutical industry, having previously served as CEO of August Bioservices and in senior roles at AmerisourceBergen and Baxter Healthcare. She replaces Mark Baum, who resigned to focus on his role at Harrow Health. Eton's CEO, Sean Brynjelsen, expressed confidence in Adams' ability to support product launches and commercial growth. Eton focuses on developing treatments for rare diseases and has multiple FDA-approved products.

Positive
  • Jenn Adams brings extensive pharmaceutical industry experience, which could enhance Eton's strategic direction.
  • Her previous leadership roles indicate potential for growth in Eton's commercial organization.
Negative
  • The resignation of Mark Baum could create a continuity gap in leadership during a transformative period for the company.

DEER PARK, Ill., March 17, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17, 2021. Ms. Adams brings extensive commercial, operational, and leadership experience in the pharmaceutical industry.

“We are pleased to have Jenn join our board. Her experience growing pharmaceutical companies and leading sales organizations will be valuable to Eton as we continue to launch products and grow our commercial organization,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Ms. Adams’ experience includes leading and growing both Fortune 500 public and private equity-backed companies. She currently serves as CEO of August Bioservices, a leading provider of research, development, and manufacturing services to pharmaceutical and biotechnology companies. Prior to joining August Bioservices, she served as SVP & President of AmerisourceBergen’s Clinical Product Solutions Business Unit. Ms. Adams spent her early career at Baxter Healthcare, serving in leadership roles in its Medication Delivery and Fenwal businesses. Ms. Adams also serves as a Senior Advisor to Oak HC/FT, a venture growth-equity fund investing in healthcare information and services. Ms. Adams serves on the nonprofit Board of LifeScience Tennessee and holds an MBA from the Northwestern University’s J.L. Kellogg Graduate School of Management.

Ms. Adams replaces Mark Baum, who stepped down from the board effective March 17 in order to devote more time to Harrow Health Inc., where he serves as Chief Executive Officer. “We are grateful for Mark’s service and valuable contributions. His vision helped to create Eton and his service was instrumental in growing the company to where it is today,” said Sean Brynjelsen.

About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway Preservative Free®, and has six additional products that have been submitted to the FDA.

Company Contact:
David Krempa
dkrempa@etonpharma.com
612-387-3740


FAQ

Who is Jenn Adams and what is her role at Eton Pharmaceuticals?

Jenn Adams has been appointed to the board of directors at Eton Pharmaceuticals, bringing extensive experience in the pharmaceutical industry.

Why did Mark Baum resign from Eton Pharmaceuticals?

Mark Baum stepped down to dedicate more time to his role as CEO of Harrow Health Inc.

What impact could Jenn Adams' appointment have on Eton Pharmaceuticals?

Her experience in growing pharmaceutical companies may enhance Eton's product launches and commercial growth strategy.

What are some of Eton Pharmaceuticals' products?

Eton Pharmaceuticals owns or receives royalties from three FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway Preservative Free®.

Eton Pharmaceutcials, Inc.

NASDAQ:ETON

ETON Rankings

ETON Latest News

ETON Stock Data

325.38M
25.24M
5.39%
33.36%
0.74%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
DEER PARK